ロード中...
Uptake of Ranibizumab but Not Bevacizumab into Uveal Melanoma Cells Correlates with a Sustained Decline in VEGF-A Levels and Metastatic Activities
Despite the implication of vascular endothelial growth factor-A (VEGF-A) in the pathophysiology of uveal melanoma (UM), the anti-VEGF-A antibody bevacizumab yielded conflicting results on UM growth. Here, we evaluated whether bevacizumab and ranibizumab, a humanized Fab-fragment against VEGF-A, can...
保存先:
| 出版年: | Cancers (Basel) |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6628228/ https://ncbi.nlm.nih.gov/pubmed/31234419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11060868 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|